We, all stakeholders, must be able to create the framework for recognising the real value in continuous innovation on existing molecules.
In Conversation
In my opinion, the regulatory authority, the State Institute for Drug Control (SUKL), is strict but fair
When it comes to the academic environment — universities, research institutes, etc. science in the Czech Republic is supported very strongly, more now than ever before.…
We have quite a significantly sized clinical trial team here in Hungary – even larger than our marketing team in fact
My mission was to set the systems, structures, mindsets and capabilities in order to be at the avant-garde of this transformation because I would rather be…
The most noticeable change [in the Hungarian healthcare landscape] is the speed of information sharing by companies and the amount available to the patients
We are often approached by consultants trying to teach us how to become more profitable and internationalize. I usually dismiss them because, even though we sometimes…
Mundipharma operates in a unique way because while it is a multinational company, it operates under the notion of independent associated companies, meaning that each legal…
Medical aesthetics is a beautiful business that will grow – I predict it will double or even triple in the next few years
Sweden has many startups and biotechnology companies, which offers a great window of opportunity for PPD to contribute to the regional industry's R&D efforts
The Czech Republic, considering its size, is a very important partner for Germany
AOP Orphan is a highly specialized company that truly caters to a niche segment of rare diseases.
